Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Refractory ulcer of reconstructed gastric tube after esophagectomy: a case report.

Okamura Y, Takeno S, Takahashi Y, Moroga T, Yamashita S, Kawahara K.

Ann Thorac Cardiovasc Surg. 2013;19(2):136-9. Epub 2012 Aug 31.

2.

Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.

Inaba T, Mizuno M, Kawai K, Yokota K, Oguma K, Miyoshi M, Take S, Okada H, Tsuji T.

J Gastroenterol Hepatol. 2002 Jul;17(7):748-53.

PMID:
12121503
3.
4.

A comparative study on endoscopic ulcer healing of omeprazole versus rabeprazole with respect to CYP2C19 genotypic differences.

Ando T, Kato H, Sugimoto N, Nagao Y, Seto N, Hongo H, Kajikawa H, Isozaki Y, Shimozawa M, Naito Y, Yoshida N, Ishizaki T, Yoshikawa T.

Dig Dis Sci. 2005 Sep;50(9):1625-31.

PMID:
16133961
5.

Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.

Sahara S, Sugimoto M, Uotani T, Ichikawa H, Yamade M, Iwaizumi M, Yamada T, Osawa S, Sugimoto K, Umemura K, Miyajima H, Furuta T.

Aliment Pharmacol Ther. 2013 Nov;38(9):1129-37. doi: 10.1111/apt.12492. Epub 2013 Sep 16.

6.

Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.

Saitoh T, Fukushima Y, Otsuka H, Hirakawa J, Mori H, Asano T, Ishikawa T, Katsube T, Ogawa K, Ohkawa S.

Aliment Pharmacol Ther. 2002 Oct;16(10):1811-7.

7.

Endoscopic analysis of gastric ulcer after one week's treatment with omeprazole and rabeprazole in relation to CYP2C19 genotype.

Ando T, Ishikawa T, Kokura S, Naito Y, Yoshida N, Yoshikawa T.

Dig Dis Sci. 2008 Apr;53(4):933-7. Epub 2007 Oct 13.

PMID:
17934830
8.

Rabeprazole: an update of its use in acid-related disorders.

Carswell CI, Goa KL.

Drugs. 2001;61(15):2327-56. Review.

PMID:
11772142
9.

Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.

Zhao F, Wang J, Yang Y, Wang X, Shi R, Xu Z, Huang Z, Zhang G.

Helicobacter. 2008 Dec;13(6):532-41. doi: 10.1111/j.1523-5378.2008.00643.x.

PMID:
19166419
10.

Comparison of four proton pump inhibitors for the short-term treatment of esophagitis in elderly patients.

Pilotto A, Franceschi M, Leandro G, Scarcelli C, D'Ambrosio LP, Paris F, Annese V, Seripa D, Andriulli A, Di Mario F.

World J Gastroenterol. 2007 Sep 7;13(33):4467-72.

11.

Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.

Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Sugimura H, Ohashi K, Ishizaki T, Kaneko E.

Clin Pharmacol Ther. 2001 Mar;69(3):158-68.

PMID:
11240980
12.
13.
14.

Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin.

Kawabata H, Habu Y, Tomioka H, Kutsumi H, Kobayashi M, Oyasu K, Hayakumo T, Mizuno S, Kiyota K, Nakajima M, Kimoto K, Inokuchi H, Kawai K.

Aliment Pharmacol Ther. 2003 Jan;17(2):259-64.

15.

Comparison of the efficacy of rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of peptic ulcer diseases.

Ji S, Kim HS, Kim JW, Jee MK, Park KW, Uh Y, Lee DK, Song JS, Baik SK, Kwon SO.

J Gastroenterol Hepatol. 2006 Sep;21(9):1381-7.

PMID:
16911680
16.

Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient.

Furuta T, Takashima M, Shirai N, Xiao F, Hanai H, Ohashi K, Ishizaki T.

Clin Pharmacol Ther. 2000 Jun;67(6):684-9. Review.

PMID:
10872651
17.

CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects.

Sakai T, Aoyama N, Kita T, Sakaeda T, Nishiguchi K, Nishitora Y, Hohda T, Sirasaka D, Tamura T, Tanigawara Y, Kasuga M, Okumura K.

Pharm Res. 2001 Jun;18(6):721-7.

PMID:
11474773
18.

High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin.

Furuta T, Shirai N, Xiao F, Takashita M, Sugimoto M, Kajimura M, Ohashi K, Ishizaki T.

Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.

PMID:
14696516
19.

Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP2C19 genotype in Japanese.

Sugimoto M, Shirai N, Nishino M, Kodaira C, Uotani T, Sahara S, Ichikawa H, Kagami T, Sugimoto K, Furuta T.

Eur J Clin Pharmacol. 2014 Sep;70(9):1073-8. doi: 10.1007/s00228-014-1713-y. Epub 2014 Jul 6.

PMID:
24996380
20.

Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.

Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Inaba T, Yamamoto K, Okada H, Yokota K, Oguma K, Shiratori Y.

Am J Gastroenterol. 2003 Nov;98(11):2403-8.

PMID:
14638340
Items per page

Supplemental Content

Write to the Help Desk